The integration into Rightway's modern PBM combines the transparent pricing of Cost Plus Drugs with Rightway's signature member experience, granting members direct access to the pharmacy.
Mark Cuban's drug company, Cost Plus Drugs, has added healthcare company Rightway to its network. This marks the first time a Pharmacy Benefit Manager (PBM) has added the pharmacy to its network.
This relationship grants members of Rightway's PBM direct access to all medications available through Cost Plus Drugs, according to a news release.
Rising pharmacy costs are one of the fastest-growing components employers are seeing within their companies. PBMs are leaving employers and patients with few options to curb rising costs.
Cost Plus Drugs has built a parallel supply chain, sidestepping the limitations of the current PBM landscape altogether and unlocking an unprecedented level of transparency, flexibility and availability for consumers to fill their generic prescriptions. The prices at Cost Plus Drugs are at cost with a 15% markup. Prescriptions are delivered by mail, further lowering the cost per pill as mail-order medications are dispensed in greater quantities.
The integration into Rightway's modern PBM combines the transparent pricing of Cost Plus Drugs with Rightway's signature member experience, granting members direct access to the pharmacy from within the Rightway mobile app.
"Rightway's relationship with Cost Plus Drugs demonstrates our commitment to making it as easy as possible for members to get the absolute lowest price available for their prescriptions," said Scott Musial, Chief Pharmacy Officer of Rightway, in the release. "Cost Plus Drugs offers some of the lowest prices in the market. It enables Rightway to step away from the traditional supply chain, offering our members greater choice, lowering their spending, and giving them back time they'd spend at the pharmacy. Entrants like Cost Plus Drugs are welcome warriors in the battle against sky-high drug prices."
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
Positive Pipeline Updates for Friedreich’s Ataxia
October 24th 2024After experiencing setbacks, PTC reported positive results for vatiquinone, its selective inhibitor of 15-Lipoxygenase (15-LO) enzyme, regulator of the energetic and oxidative stress pathways that are disrupted in Friedreich ataxia
Read More